bioRxivCancer Biology
Attribution of Cancer Origins to Endogenous, Exogenous, and Actionable Mutational Processes
Abstract
Mutational processes in tumors leave tell-tale genomic signatures composed of "passenger" mutations and mutations that have quantifiable effects on the proliferation and survival of cancer cell lineages. We identify the contributions of mutational processes to each oncogenic variant, quantifying responsibility for origination of changes at oncogenic variant sites contributing to tumorigenesis in 23 cancer types. We demonstrate that the variants driving melanomas and lung cancers are predominantly attributable to the actionable, preventable, exogenous mutational processes of ultraviolet light and tobacco exposure, whereas gliomas and prostate adenocarcinomas are largely attributable to endogenous processes associated with aging. Preventable mutations associated with pathogen exposure and APOBEC activity account for a large proportion of the cancer effect within head and neck, bladder, cervical, and breast cancers. These attributions complement epidemiological approaches--revealing the burden of cancer driven by single-nucleotide variants caused by either endogenous or exogenous, non-actionable or actionable processes, and crucially inform cancer prevention.
- organism: human
- assay: whole-genome sequencing
- research focus: cancer & tumor microenvironment
- research focus: variant effect prediction
- approach: statistical model
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Mutational signatures associated with tobacco smoking in human cancer
Ludmil B Alexandrov, Young Seok Ju, … Michael R Stratton·SciencePeer-reviewed·Nov 4, 2016
- The effects of mutational process and selection on driver mutations across cancer types
D. Temko, I. Tomlinson, … T. Graham·bioRxiv·Jun 12, 2017
- Germline determinants of the somatic mutation landscape in 2,642 cancer genomes
Lauri A. Aaltonen, Federico Abascal, … Johann Sebastian De Bono·NaturePeer-reviewed·Feb 5, 2020
- Optimal pathways control fixation of multiple mutations during cancer initiation
H. Teimouri, C. Spaulding, A. B. Kolomeisky·bioRxiv·Feb 7, 2022
- The Repertoire of Mutational Signatures in Human Cancer
L. Alexandrov, J. Kim, … M. R. Stratton·bioRxiv·Jul 3, 2019
- When will the cancer start? Elucidating the correlations between cancer initiation times and lifetime cancer risks
H. Teimouri, M. Kochugaeva, A. B. Kolomeisky·bioRxiv·May 17, 2019